Download PDF
Thromb Haemost 2009; 101(01): 62-67
DOI: 10.1160/TH08-08-0502
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Polymorphisms in the protein C gene as risk factor for venous thrombosis

Elisabeth R. Pomp
1   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
,
Carine J. M. Doggen
1   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
,
Hans L. Vos
2   Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
3   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Pieter H. Reitsma
2   Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
3   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Frits R. Rosendaal
1   Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
3   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
› Author AffiliationsFinancial support: This research was supported by the Netherlands Heart Foundation (NHS 98.113), the Dutch Cancer Foundation (RUL 99/1992) and the Netherlands Organisation for Scientific Research (912–03–033| 2003).
Further Information

Publication History

Received: 04 August 2008

Accepted after minor revision: 19 September 2008

Publication Date:
23 November 2017 (online)

    Permissions and Reprints

Summary

Protein C is an important inhibitor of blood coagulation. We investigated the effect of two polymorphisms within the promoter region of the protein C gene (C/T at position 2405 and A/G at position 2418) on risk of venous thrombosis and on plasma protein C levels. In addition the combined effect of the two polymorphisms with factor V Leiden and oral contraceptive use was investigated. Previous studies on these polymorphisms were small and were not able to investigate synergistic effects. In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study), protein C levels were determined in 2,043 patients with venous thrombosis and 2,857 control subjects, and the two polymorphisms in 4,285 patients and 4,863 control subjects. The CC/GG genotype was associated with the lowest protein C levels. Compared to carriers of the TT/AA genotype – a genotype associated with higher protein C levels – the risk of venous thrombosis in CC/GG carriers was 1.3-fold increased (95% confidence interval 1.09–1.48). The combination of factor V Leiden with the CC/GG genotype led to a 4.7-fold increased risk, compared to non-carriers with the TT/AA genotype. Oral contraceptive use together with the CC/ GG genotype resulted in a 5.2-fold increased risk. In conclusion, the CC/GG genotype is associated with lower levels of protein C and an elevated risk of venous thrombosis compared to the TT/AA genotype. There is no clear synergistic effect of the CC/ GG genotype with factor V Leiden or oral contraceptive use on thrombotic risk.

Keywords

Case-control study - polymorphisms - protein C - risk factors - venous thrombosis
 

  • References

  • 1 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-11131.
    PubMedGoogle Scholar
  • 2 Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 1989; 114: 528-534.
    CrossrefPubMedGoogle Scholar
  • 3 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344.
    CrossrefPubMedGoogle Scholar
  • 4 Horellou MH, Conard J, Bertina RM. et al. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J (Clin Res Ed) 1984; 289: 1285-1287.
    CrossrefPubMedGoogle Scholar
  • 5 Griffin JH, Evatt B, Zimmerman TS. et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
    CrossrefPubMedGoogle Scholar
  • 6 Emmerich J, Vossen CY, Callas PW. et al. Chronic venous abnormalities in symptomatic and asymptomatic protein C deficiency. J Thromb Haemost 2005; 03: 1428-1431.
    CrossrefPubMedGoogle Scholar
  • 7 Koster T, Rosendaal FR, Briët E. et al. Protein C deficiency in a controlled series of unselected out-patients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.
    PubMedGoogle Scholar
  • 8 Conlan MG, Folsom AR, Finch A. et al. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 762-767.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Tait RC, Walker ID, Islam SI. et al. Protein C activity in healthy volunteers--influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993; 70: 281-285.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Spek CA, Koster T, Rosendaal FR. et al. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995; 15: 214-218.
    CrossrefPubMedGoogle Scholar
  • 11 Aiach M, Nicaud V, Alhenc-Gelas M. et al. Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1999; 19: 1573-1576.
    CrossrefPubMedGoogle Scholar
  • 12 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
    CrossrefPubMedGoogle Scholar
  • 13 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
    CrossrefPubMedGoogle Scholar
  • 14 Koeleman BP, Reitsma PH, Allaart CF. et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
    PubMedGoogle Scholar
  • 15 Vandenbroucke JP, Koster T, Briët E. et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
    CrossrefPubMedGoogle Scholar
  • 16 Hartge P, Brinton LA, Rosenthal JF. et al. Random digit dialing in selecting a population-based control group. Am J Epidemiol 1984; 120: 825-833.
    CrossrefPubMedGoogle Scholar
  • 17 Blom JW, Doggen CJM, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
    CrossrefPubMedGoogle Scholar
  • 18 Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
    CrossrefPubMedGoogle Scholar
  • 19 Lowe GDO, Woodward M, Vessey M. et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-535.
    Article in Thieme ConnectPubMedGoogle Scholar